trending Market Intelligence /marketintelligence/en/news-insights/trending/sly9ecl81na5-5dgv6qcpq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Homology Medicines discloses share count for IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Homology Medicines discloses share count for IPO

Homology Medicines Inc. plans to sell 7,667,050 common shares at a price between $14.00 and $16.00 apiece to raise about $122.7 million in an IPO on the Nasdaq Global Select Market.

The shares include 1,000,050 common shares offered to the underwriters as an overallotment option.

The Bedford, Mass.-based genetic medicines company expects shares to start trading under the FIXX symbol following the pricing of the offering.

Net proceeds from the offering are expected to be about $90.2 million, assuming an initial public offering price of $15.00 per share. The net proceeds will be roughly $104.1 million if the underwriters fully exercise their overallotment option.

Homology plans to use net proceeds of about $18.0 million to $20.0 million to develop HMI-102 to treat a rare inherited disorder known as phenylketonuria, through preclinical studies and a phase 1/2 study. It plans to use about $8.0 million to $10.0 million of the proceeds to nominate its lead gene editing product candidate and advance this program through preclinical studies.

About $15.0 million to $20.0 million will be used to build out internal manufacturing capacity that complies with current good manufacturing practice regulations and is sufficient for the clinical supply of product.

In addition, about $2.0 million to $3.0 million of the proceeds will be used to expand Homology's intellectual property portfolio to further protect the company's proprietary adeno-associated virus vectors and other aspects of the technology platform.

Adeno-associated viruses are small viruses with a genome of single-stranded DNA. They can insert genetic material at a specific site on chromosome 19 with near 100% certainty.

The company's proprietary platform is designed to utilize its adeno-associated virus vectors, derived from human hematopoietic stem cells, to precisely and efficiently deliver genetic medicines either through a gene therapy or a nuclease-free gene editing modality across a range of genetic disorders.

The remaining proceeds will fund new and ongoing research and development activities in the company's CNS, hemoglobinopathy and other programs, and for working capital and other general corporate purposes.

Merrill Lynch Pierce Fenner & Smith Inc., Cowen and Co. LLC, Evercore Group LLC and BTIG LLC are acting as underwriters for the offering.